Literature DB >> 17918015

Febrile neutropenia in children with cancer: a retrospective Norwegian multicentre study of clinical and microbiological outcome.

Niklas Stabell1, Ellen Nordal, Einar Stensvold, Karianne Wiger Gammelsrud, Bendik Lund, Arne Taxt, Frauke Buhring, Margrethe Greve-Isdahl, Hans Petter Fornebo, Gunnar Skov Simonsen, Claus Klingenberg.   

Abstract

Our objective was to describe clinical and laboratory characteristics, treatment and outcome among Norwegian children with cancer suffering from chemotherapy-induced febrile neutropenia (FN). We retrospectively reviewed data on paediatric FN episodes in 7 Norwegian hospitals during a 2.5-y period. A total of 236 episodes of FN occurred in 95 children. Acute lymphoblastic leukaemia was the most common diagnosis (49 patients). Blood cultures yielded growth in 39 episodes (17%). Primary empirical antibiotic regimens could be assigned to 2 main groups: 1) benzylpenicillin or ampicillin and an aminoglycoside (58%) or 2) a regimen based on third-generation cephalosporins (42%). There were no statistically significant differences in outcome between the 2 regimens in terms of need to change initial antibiotic treatment, d of fever or maximum C-reactive protein values. One infection-related death (fungal septicaemia) occurred during the study period. We conclude that incidence of septicaemia and clinical outcome is similar to recent international trials on paediatric FN, but antibiotic treatment in Norway differs from international guidelines. However, patients in our study were successfully and safely treated, irrespective of the primary empirical antibiotic regimen.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17918015     DOI: 10.1080/00365540701670436

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  6 in total

1.  Febrile illness in high-risk children: a prospective, international observational study.

Authors:  Fabian J S van der Velden; Gabriella de Vries; Alexander Martin; Emma Lim; Ulrich von Both; Laura Kolberg; Enitan D Carrol; Aakash Khanijau; Jethro A Herberg; Tisham De; Rachel Galassini; Taco W Kuijpers; Federico Martinón-Torres; Irene Rivero-Calle; Clementien L Vermont; Nienke N Hagedoorn; Marko Pokorn; Andrew J Pollard; Luregn J Schlapbach; Maria Tsolia; Irini Elefhteriou; Shunmay Yeung; Dace Zavadska; Colin Fink; Marie Voice; Werner Zenz; Benno Kohlmaier; Philipp K A Agyeman; Effua Usuf; Fatou Secka; Ronald de Groot; Michael Levin; Michiel van der Flier; Marieke Emonts
Journal:  Eur J Pediatr       Date:  2022-10-15       Impact factor: 3.860

2.  Etiology and clinical course of febrile neutropenia in children with cancer.

Authors:  Hana Hakim; Patricia M Flynn; Katherine M Knapp; Deo Kumar Srivastava; Aditya H Gaur
Journal:  J Pediatr Hematol Oncol       Date:  2009-09       Impact factor: 1.289

Review 3.  Advances in the treatment of neutropenia.

Authors:  David C Dale
Journal:  Curr Opin Support Palliat Care       Date:  2009-09       Impact factor: 2.302

Review 4.  Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.

Authors:  Kjeld Schmiegelow; Klaus Müller; Signe Sloth Mogensen; Pernille Rudebeck Mogensen; Benjamin Ole Wolthers; Ulrik Kristoffer Stoltze; Ruta Tuckuviene; Thomas Frandsen
Journal:  F1000Res       Date:  2017-04-07

Review 5.  Predicting infectious complications in neutropenic children and young people with cancer (IPD protocol).

Authors:  Robert S Phillips; Alex J Sutton; Richard D Riley; Julia C Chisholm; Susan V Picton; Lesley A Stewart
Journal:  Syst Rev       Date:  2012-02-09

6.  Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis.

Authors:  Robert S Phillips; Lillian Sung; Roland A Ammann; Richard D Riley; Elio Castagnola; Gabrielle M Haeusler; Robert Klaassen; Wim J E Tissing; Thomas Lehrnbecher; Julia Chisholm; Hana Hakim; Neil Ranasinghe; Marianne Paesmans; Ian M Hann; Lesley A Stewart
Journal:  Br J Cancer       Date:  2016-03-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.